Navigation Links
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Date:12/9/2009

lopment and expedite the review of drugs that treat serious diseases and fill an unmet medical need based on the need for safer non-invasive tests to diagnose pancreatic disorders. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could directly benefit by the addition of RG1068.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statem
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder
2. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
3. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
4. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
8. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
9. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
10. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
11. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 GenSpera, Inc. ... the treatment of cancer, announces the recent publication of ... Steroids . The recent article co-authored ... the evolution and development of GenSpera,s prodrug technology platform that ... thapsigargin (from the plant Thapsia garganica ) directly ...
(Date:8/28/2014)... MONROVIA, Calif. , Aug. 28, 2014  STAAR Surgical ... and marketer of implantable lenses and delivery systems for the ... 2014 Health Care Conference at the New York Palace Hotel ... Barry Caldwell , President and CEO will ... financial results, and operational developments and be joined by ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
(Date:8/28/2014)... To kick off the fall season ... One Spas retailers across the country are offering 0% ... The Hot Tub Tailgate Event is from August 29th-September ... more information and to apply early! , As the ... wide variety of outdoor hot tubs with exclusive features ...
(Date:8/28/2014)... 28, 2014) A fortuitous collaboration at Rice ... a recently discovered natural antibiotic. , The laboratory ... someday help bolster the fight against bacteria that ... around the world. , As part of ... structural biologist Yousif Shamoo and their colleagues created ...
(Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
(Date:8/28/2014)... be treated with nasal septum cells. Researchers at the ... cells taken from the nasal septum are able to ... can thus repair articular cartilage defects. The nasal cartilage ... environment is associated with the expression of so-called HOX ... has published the research results together with the report ...
(Date:8/28/2014)... OTTAWA, August 28, 2014 One in every 200 ... with the number of people living with the disease ... according to a study by researchers at the Institute ... Eastern Ontario (CHEO), and the Ottawa Hospital Research Institute. ... prevalence in the world. , The study, published this ...
Breaking Medicine News(10 mins):Health News:Synthesis produces new antibiotic 2Health News:Synthesis produces new antibiotic 3Health News:Synthesis produces new antibiotic 4Health News:From nose to knee: Engineered cartilage regenerates joints 2Health News:Ontario has one of the highest rates of IBD in the world 2
... caries can destroy most of a child,s teeth by ... Indians and Alaskan natives. Although the link between ... has been known for almost a century, progress in ... the disease has remained elusive. The ...
... The American College of Physicians (ACP) today told the ... including enacting a permanent end to scheduled Medicare sustainable ... for Congress to act was demonstrated by today,s release ... across-the-board cut in Medicare payments to doctors on January ...
... , THURSDAY, Nov. 3 (HealthDay News) -- Allergy ... costs and can now provide relief to allergy sufferers ... And while allergy shots are currently given under the ... investigated, delegates heard at this week,s annual scientific meeting ...
... the first time, researchers have combined gene therapy ... severe, crippling bleeding disorder hemophilia A in large ... new therapies for human patients. Researchers at ... Medicine, collaborating with other institutions, report in ...
... HealthDay Reporter , WEDNESDAY, Nov. 2 (HealthDay News) -- ... subset of hard-to-treat hemophilia patients also seems to be effective ... this study, published in the Nov. 3 edition of the ... one and didn,t last long, the results do raise the ...
... Men with locally advanced or high-risk prostate cancer who ... are less likely to die from their disease, shows ... Margaret Hospital (PMH) Cancer Program, University Health Network. ... Lancet (doi: 10.1016/S0140-6736(11)61095-7). Principal investigator Padraig Warde, ...
Cached Medicine News:Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 2Health News:NYUCD awarded $2.2 million NIH grant to decode genome of caries-causing bacteria 3Health News:Congress must 'go big' on physician payment reform 2Health News:Congress must 'go big' on physician payment reform 3Health News:Improved Allergy Shots Might Be on Horizon 2Health News:Gene therapy shows promise as hemophilia treatment in animal studies 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 2Health News:Using Drug for Prevention Might Help in Hard-to-Treat Hemophilia 3Health News:Radiation plus hormone therapy greatly improves survival 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: